Taiwan · Delayed Price · Currency is TWD OBI Pharma Company Description
OBI Pharma, Inc., a clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally.
The company’s pipeline products include Adagloxad simolenin which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424 which has completed phase 2 for the treatment of liver hepatocellular carcinoma and acute lymphocytic leukemia; OBI-992 which is in phase 1 for the treatment of solid tumors; OBI-902 and OBI-904 that are in preclinical stage for the treatment of solid tumors; BsADC which is in discovery stage for the treatment of solid tumors.
It also engages in investing and trading; and manufacture and wholesale of western pharmaceuticals, as well as research and development of biotechnology.
OBI Pharma, Inc. was founded in 2002 and is headquartered in Taipei, Taiwan.
Contact Details
Address: No. 508, Sec. 7 Taipei, 115 Taiwan | |
| Phone | 886 2 2655 8799 |
| Website | obipharma.com |
Stock Details
| Ticker Symbol | 4174 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0004174008 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Heidi Wang Ph.D. | Chief Executive Officer and Director |
| Colin Kao | Chief Operating Officer and Finance Director |
| Ya-Chi Chen | Chief Scientific Officer |
| Po-Jen Chang | Director of Human Resources and Administration |
| Sharon Lee | Director of Public Affairs |
| Kevin P. Poulos | Chief Business Officer of OBI Pharma USA, Inc. |
| Dr. Dong Xu Ph.D. | Chief Medical Officer of OBI Pharma USA, Inc. |
| Wade Liu | Head of Global Manufacturing and Supply Chain |
| Chun-Hung Chou | Vice President of Chemical Pharmacy and Research & Development Office |